Amgen's IMDELLTRA Combo Shows OS Gains; Opdivo Biosimilar Filed
AMGN sits 43% above its 52-week low of $269.77 on elevated volume (3.2× avg).
Summary
Amgen's Q2 revenue topped $10B, but the new material is pipeline progress: Phase III IMDELLTRA + durvalumab showed significant OS, PFS, and ORR gains in first-line maintenance ES-SCLC, and the FDA cut infusion monitoring from 22-24h to 6-8h. The company also filed for FDA approval of its Opdivo biosimilar and expects to be in the first wave. Management is using AmgenNow DTC data to guide MariTide commercial planning, with a Phase III obesity program of about a dozen trials and OSA enrollment completed in August 2026. These updates add to the Q2 beat already reported on August 4, but the new clinical and regulatory details are material for the pipeline narrative.
At the time of this announcement, AMGN was trading at $386.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $208.5B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.